Table 4 Univariable and multivariable analyses for progression-free survival following completion of chemoimmunotherapy, with estimated effect (Est), 95% confidence interval (CI) and statistical significance for all potential covariates. ECOG: Eastern cooperative oncology group, NMP: non-malignant phenotype. *Samples with no available information were excluded.

Age (years)

<75

Reference

≥75

0.735 (0.397, 1.358)

0.325

ECOG performance score

0–1

Reference

2–3

0.752 (0.266, 2.124)

0.591

Sex

Female

Reference

Male

1.127 (0.539, 2.36)

0.75

Binet stage

A/B

Reference

C

1.022 (0.558, 1.872)

0.944

IgHV mutational status

Mutated

Reference

Unmutated

1.691 (0.834, 3.426)

0.145

11p deletion

No

Reference

Yes

2.045 (0.889, 4.704)

0.092

13q deletion

No

Reference

Yes

1.151 (0.622, 2.127)

0.654

Trisomy 12

No

Reference

Yes

0.728 (0.335, 1.581)

0.422

Chemotherapy received

Chlorambucil

Reference

Bendamustine

0.604 (0.326, 1.122)

0.111

Idelalisib randomisation

Placebo

Reference

Reference

Idelalisib

0.427 (0.223, 0.817)

0.01

0.630 (0.321, 1.238)

0.18

Post-treatment FBC:

Haemoglobin (g/dL)

≥12

Reference

Reference

<12

3.211 (1.678, 6.143)

0.0004

3.484 (1.649, 7.364)

0.001

Neutrophil count (x10^9/L)

≥1.5

Reference

<1.5

1.255 (0.297, 5.297)

0.757

Platelet count (x10^9/L)

≥150

Reference

<150

1.566 (0.856, 2.865)

0.146

Post-treatment immunoglobulin levels:

Serum IgG (g/L)*

Continuous

1.036 (0.936, 1.146)

0.498

Serum IgA (g/L)*

Continuous

0.97 (0.785, 1.199)

0.78

Serum IgM (g/L)*

Continuous

0.9 (0.684, 1.185)

0.454

Post-treatment MRD

<0.1%

Reference

Reference

≥0.1%

3.63 (1.527, 8.628)

0.004

4.94 (1.858, 13.133)

0.001

NMP clusters

Continuous

0.953 (0.92, 0.987)

0.007

0.958 (0.924, 0.993)

0.019